abiraterone |
|
2D6 moderate inhibitor |
|
|
|
|
|
|
|
|
acyclovir |
|
|
1A2 weak inhibitor |
|
|
|
|
|
|
|
adefovir1
|
|
|
|
|
|
|
|
|
|
OAT1 substrate |
alfentanil |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
allopurinol |
|
|
1A2 weak inhibitor |
|
|
|
|
|
|
|
alosetron |
|
|
|
|
|
|
1A2 sensitive substrate |
|
|
|
alprazolam |
|
|
|
|
|
|
|
3A4 moderate sensitive substrate |
|
|
amiodarone |
|
2C9 moderate inhibitor |
2D6; 3A4 weak inhibitor |
|
|
|
|
|
P-gp inhibitor |
|
apalutamide |
|
|
|
3A4 strong inducer |
2C19 moderate inducer |
2C9 weak inducer |
|
|
|
|
aprepitant |
|
|
|
|
|
2C9 weak inducer |
|
3A4 moderate sensitive substrate |
|
|
aprepitant |
|
3A4 moderate inhibitor |
|
|
|
|
|
|
|
|
armodafinil |
|
|
|
|
|
3A4 weak inducer |
|
|
|
|
atazanavir and ritonavir |
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3 inhibitor |
|
atomoxetine |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
atorvastatin |
|
|
|
|
|
|
|
3A4 moderate substrate |
|
OATP1B1; OATP1B3 substrate |
avanafil |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
baricitinib |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
bosentan |
|
|
|
|
3A4 moderate inducer |
|
|
|
|
OATP1B1; OATP1B3 substrate |
budesonide |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
bumetanide |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
bupropion2
|
2D6 strong inhibitor |
|
|
|
|
|
2B6 sensitive substrate |
|
|
|
buspirone |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
caffeine |
|
|
|
|
|
|
1A2 sensitive substrate |
|
|
|
carbamazepine |
|
|
|
2B6; 3A4 strong inducer |
|
2C9 weak inducer |
|
|
|
|
cefaclor |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
ceftizoxime |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
celecoxib3
|
|
|
2D6 weak inhibitor |
|
|
|
2C9 sensitive substrate |
|
|
|
cenobamate4
|
|
2C19 moderate inhibitor |
|
|
CYP3A4 moderate inducer b |
|
|
|
|
|
ceritinib |
3A4 strong inhibitor |
|
2C9 weak inhibitor |
|
|
|
|
|
|
|
chlorzoxazone |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
cilostazol |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
cimetidine |
|
|
3A4; 1A2; 2D6 weak inhibitor |
|
|
|
|
|
OCT2; MATE1; MATE2-K inhibitor |
|
cinacalcet |
|
2D6 moderate inhibitor |
|
|
|
|
|
|
|
|
ciprofloxacin |
1A2 strong inhibitor |
3A4 moderate inhibitor |
|
|
|
|
|
|
|
OAT1; OAT3 substrate |
clarithromycin |
3A4 strong inhibitor |
|
|
|
|
|
|
P-gp inhibitor |
OATP1B1; OATP1B3 inhibitor |
|
clobazam |
|
|
2D6 weak inhibitor |
|
|
|
|
|
|
|
clopidogrel |
|
2C8 moderate inhibitor |
2B6 weak inhibitor |
|
|
|
|
|
|
|
clotrimazole |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
clozapine |
|
|
|
|
|
|
|
1A2 moderate sensitive substrate |
|
|
cobicistat |
3A4 strong inhibitor |
|
2D6 weak inhibitor |
|
|
|
|
|
P-gp inhibitor |
|
colchicine |
|
|
|
|
|
|
|
3A4 moderate sensitive substrate |
|
|
conivaptan |
|
3A4 moderate inhibitor5
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
crizotinib |
|
3A4 moderate inhibitor |
|
|
|
|
|
|
|
|
curcumin |
|
|
|
|
|
|
|
|
BCRP inhibitor |
|
cyclosporine |
|
3A4 moderate inhibitor |
|
|
|
|
|
|
P-gp; BCRP; OATP1B1; OATP1B3 inhibitor |
|
dabigatran etexilate |
|
|
|
|
|
|
|
|
|
P-gp substrate |
dabrafenib |
|
|
|
|
3A4 moderate inducer |
2C9 weak inducer |
|
|
|
|
darifenacin |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
darolutamide |
|
|
|
|
|
|
|
|
BCRP; OATP1B1; OATP1B3 inhibitor |
|
darunavir6
|
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
dasatinib |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
deferasirox |
|
2C8 moderate inhibitor |
|
|
|
|
|
|
|
|
desipramine |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
dextromethorphan |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
diazepam |
|
|
|
|
|
|
|
2C19 moderate sensitive substrate |
|
|
digoxin |
|
|
|
|
|
|
|
|
|
P-gp substrate |
diltiazem7
|
|
3A4 moderate inhibitor |
|
|
|
|
|
|
|
|
diosmin |
|
|
2C9 weak inhibitor |
|
|
|
|
|
|
|
disulfiram |
|
|
2C9 weak inhibitor |
|
|
|
|
|
|
|
docetaxel |
|
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3 substrate |
dolutegravir |
|
|
|
|
|
|
|
|
OCT2 inhibitor |
|
dronedarone |
|
3A4 moderate inhibitor |
|
|
|
|
3A4 sensitive substrate |
|
P-gp inhibitor |
|
duloxetine |
|
2D6 moderate inhibitor |
|
|
|
|
1A2 sensitive substrate |
|
|
|
edoxaban |
|
|
|
|
|
|
|
|
|
P-gp substrate |
efavirenz |
|
|
|
|
3A4; 2B6; 2C19 moderate inducer |
|
|
2B6 moderate sensitive substrate |
|
|
elagolix |
|
|
|
|
|
3A4 weak inducer |
|
|
|
OATP1B1; OATP1B3 substrate |
eletriptan |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
eliglustat |
|
|
|
|
|
|
2D6 sensitive substrate |
3A4 moderate sensitive substrate |
|
|
eltrombopag |
|
|
|
|
|
|
|
|
BCRP; OATP1B1; OATP1B3 inhibitor |
|
elvitegravir and ritonavir |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
enzalutamide |
|
|
|
3A4 strong inducer |
2C9; 2C19 moderate inducer |
|
|
|
|
|
eplerenone |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
erythromycin |
|
3A4 moderate inhibitor |
|
|
|
|
|
|
P-gp inhibitor |
|
escitalopram |
|
|
2D6 weak inhibitor |
|
|
|
|
|
|
|
etravirine |
|
|
|
|
3A4 moderate inducer |
|
|
|
|
|
everolimus |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
famotidine |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
febuxostat |
|
|
|
|
|
|
|
|
BCRP inhibitor |
|
felbamate |
|
2C19 moderate inhibitor |
|
|
|
|
|
|
|
|
felodipine |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
fexofenadine |
|
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3; P-gp substrate |
fluconazole |
2C19 strong inhibitor |
3A4; 2C9 moderate inhibitor |
|
|
|
|
|
|
|
|
fluoxetine |
2C19; 2D6 strong inhibitor |
|
|
|
|
|
|
|
|
|
fluvastatin |
|
|
2C9 weak inhibitor |
|
|
|
|
|
|
|
fluvoxamine |
1A2; 2C19 strong inhibitor |
3A4 moderate inhibitor |
2C9; 2D6 weak inhibitor |
|
|
|
|
|
|
|
fosaprepitant |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
fostamatinib |
|
|
|
|
|
|
|
|
BCRP inhibitor |
|
furosemide |
|
|
|
|
|
|
|
|
|
OAT1; OAT3 substrate |
gemfibrozil |
2C8 strong inhibitor |
|
|
|
|
|
|
|
OAT3; OATP1B1; OATP1B3 inhibitor |
|
glimepiride |
|
|
|
|
|
|
|
2C9 moderate sensitive substrate |
|
|
glyburide |
|
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3 substrate |
grapefruit juice8
|
|
3A4 moderate inhibitor |
|
|
|
|
|
|
|
|
ibrutinib |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
idelalisib |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
imatinib |
|
3A4 moderate inhibitor |
|
|
|
|
|
|
|
|
imipramine |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
|
|
indinavir6
|
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
indinavir and ritonavir |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
isavuconazole |
|
3A4 moderate inhibitor |
|
|
|
2B6 weak inducer |
3A4 sensitive substrate |
|
OCT2; MATE1; MATE2-K inhibitor |
|
istradefylline |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
itraconazole |
3A4 strong inhibitor |
|
|
|
|
|
|
|
P-gp inhibitor |
|
ivabradine |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
ivacaftor |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
ivosidenib9
|
|
|
|
3A4 strong inducer |
|
|
|
|
|
|
ketoconazole |
3A4 strong inhibitor |
|
|
|
|
|
|
|
P-gp inhibitor |
|
labetalol |
|
|
2D6 weak inhibitor |
|
|
|
|
|
|
|
lansoprazole10
|
|
|
|
|
|
|
|
2C19 moderate sensitive substrate |
|
|
lapatinib |
|
|
|
|
|
|
|
|
P-gp inhibitor |
|
lemborexant |
|
|
|
|
|
2B6 weak inducer |
3A4 sensitive substrate |
|
|
|
lomitapide |
|
|
3A4 weak inhibitor |
|
|
|
3A4 sensitive substrate |
|
|
|
lopinavir and ritonavir |
3A4 strong inhibitor |
|
|
|
|
|
|
|
P-gp; OATP1B1; OATP1B3 inhibitor |
|
lorcaserin |
|
2D6 moderate inhibitor |
|
|
|
|
|
|
|
|
lorlatinib |
|
|
|
|
3A4 moderate inducer |
2B6; 2C9 weak inducer |
|
|
|
|
lovastatin |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
OATP1B1 substrate |
lumacaftor and ivacaftor |
|
|
|
3A4 strong inducer |
|
|
|
|
|
|
lurasidone |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
maraviroc |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
melatonin |
|
|
|
|
|
|
1A2 sensitive substrate |
|
|
|
metformin |
|
|
|
|
|
|
|
|
|
MATE1; MATE2-K; OCT2 substrate |
methotrexate |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
methoxsalen |
|
1A2 moderate inhibitor |
|
|
|
|
|
|
|
|
metoprolol |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
|
|
mexiletine |
|
1A2 moderate inhibitor |
|
|
|
|
|
|
|
|
miconazole |
|
2C9 moderate inhibitor |
|
|
|
|
|
|
|
|
midazolam |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
mirabegron |
|
2D6 moderate inhibitor |
|
|
|
|
|
|
|
|
mitotane |
|
|
|
3A4 strong inducer |
|
|
|
|
|
|
mobocertinib |
|
|
|
|
|
3A4 weak inducer |
3A4 sensitive substrate |
|
|
|
modafinil11
|
|
|
|
|
|
3A4 weak inducer |
|
|
|
|
montelukast |
|
|
|
|
|
|
|
2C8 moderate sensitive substrate |
|
|
naloxegol |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
nebivolol |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
nefazodone |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
nelfinavir |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
nevirapine |
|
|
|
|
|
2B6 weak inducer |
|
|
|
|
nisoldipine |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
nortriptyline |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
omeprazole |
|
|
2C19 weak inhibitor |
|
|
|
2C19 sensitive substrate |
|
|
|
oral contraceptives |
|
1A2 moderate inhibitor |
|
|
|
|
|
|
|
|
oseltamivir carboxylate1
|
|
|
|
|
|
|
|
|
|
OAT3 substrate |
paclitaxel |
|
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3 substrate |
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir)8
|
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
paroxetine |
2D6 strong inhibitor |
|
|
|
|
|
|
|
|
|
peginterferon alpha-2a |
|
|
1A2 weak inhibitor |
|
|
|
|
|
|
|
penicillin G |
|
|
|
|
|
|
|
|
|
OAT3 substrate |
perphenazine |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
pexidartinib |
|
|
|
|
3A4 moderate inducer |
|
|
|
|
|
phenobarbital |
|
|
|
|
3A4 moderate inducer |
|
|
|
|
|
phenytoin |
|
|
|
3A4 strong inducer |
1A2; 2C19 moderate inducer |
|
|
2C9 moderate sensitive substrate |
|
|
pimozide |
|
|
|
|
|
|
|
3A4 moderate sensitive substrate |
|
|
pioglitazone |
|
|
|
|
|
|
|
2C8 moderate sensitive substrate |
|
|
piperine |
|
2C9 moderate inhibitor |
1A2 weak inhibitor |
|
|
|
|
|
|
|
pirfenidone |
|
|
|
|
|
|
|
1A2 moderate sensitive substrate |
|
|
pitavastatin |
|
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3 substrate |
posaconazole |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
pravastatin |
|
|
|
|
|
|
|
|
|
OATP1B1; OATP1B3 substrate |
primidone |
|
|
|
|
3A4 moderate inducer |
|
|
|
|
|
probenecid |
|
|
|
|
|
|
|
|
OAT1; OAT3 inhibitor |
|
propafenone |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
P-gp inhibitor |
|
propranolol |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
|
|
quetiapine |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
quinidine |
2D6 strong inhibitor |
|
|
|
|
|
|
|
P-gp inhibitor |
|
R-venlafaxine |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
rabeprazole |
|
|
|
|
|
|
|
2C19 moderate sensitive substrate |
|
|
ramelteon |
|
|
|
|
|
|
1A2 sensitive substrate |
|
|
|
ranitidine |
|
|
3A4 weak inhibitor |
|
|
|
|
|
|
|
ranolazine |
|
|
3A4 weak inhibitor |
|
|
|
|
|
P-gp ; OCT2; MATE1; MATE2-K inhibitor |
|
repaglinide |
|
|
|
|
|
|
2C8 sensitive substrate |
|
|
OATP1B1; OATP1B3 substrate |
rifampin |
|
|
|
3A4; 2C19 strong inducer |
1A2, 2B6; 2C8; 2C9 moderate inducer |
|
|
|
OATP1B112; OATP1B312 inhibitor |
|
rilpivirine |
|
|
|
|
|
|
|
3A4 moderate sensitive substrate |
|
|
ritonavir13, 14, 15
|
3A4 strong inhibitor |
|
|
|
|
2B6; 2C9; 2C19 weak inducer |
|
|
|
|
rivaroxaban |
|
|
|
|
|
|
|
3A4 moderate sensitive substrate |
|
|
rolapitant16
|
|
2D6 moderate inhibitor |
|
|
|
|
|
|
|
BCRP inhibitor |
rosiglitazone |
|
|
|
|
|
|
|
2C8 moderate sensitive substrate |
|
|
rosuvastatin |
|
|
|
|
|
|
|
|
|
BCRP; OATP1B1; OATP1B3 substrate |
rufinamide |
|
|
|
|
|
3A4 weak inducer |
|
|
|
|
S-mephenytoin |
|
|
|
|
|
|
2C19 sensitive substrate |
|
|
|
S-venlafaxine |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
|
|
saquinavir6
|
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
saquinavir and ritonavir |
3A4 strong inhibitor |
|
|
|
|
|
|
|
P-gp inhibitor |
|
sertraline |
|
|
2D6 weak inhibitor |
|
|
|
|
|
|
|
sildenafil |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
simvastatin |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
OATP1B1; OATP1B3 substrate |
sirolimus |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
sotorasib |
|
|
|
|
3A4 moderate inducer |
|
|
|
|
|
St. John’s wort17
|
|
|
|
3A4 strong inducer |
|
|
|
|
|
|
sulfasalazine |
|
|
|
|
|
|
|
|
|
BCRP substrate |
tacrolimus |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
tadalafil |
|
|
|
|
|
|
|
3A4 moderate sensitive substrate |
|
|
tasimelteon |
|
|
|
|
|
|
1A2 sensitive substrate |
|
|
|
telithromycin |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
tenofovir1
|
|
|
2B6 weak inhibitor |
|
|
|
|
|
|
OAT1 substrate |
terbinafine |
2D6 strong inhibitor |
|
|
|
|
|
|
|
|
|
teriflunomide |
|
2C8 moderate inhibitor |
|
|
1A2 moderate inducer |
|
|
|
BCRP; OATP1B3; OAT3 inhibitor |
|
theophylline |
|
|
|
|
|
|
|
1A2 moderate sensitive substrate |
|
|
ticagrelor |
|
|
3A4 weak inhibitor |
|
|
|
3A4 sensitive substrate |
|
|
|
ticlopidine |
2C19 strong inhibitor |
|
2B6 weak inhibitor |
|
|
|
|
|
|
|
tipranavir6
|
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
tipranavir and ritonavir |
3A4 strong inhibitor |
|
|
|
|
|
|
|
|
|
tizanidine |
|
|
|
|
|
|
1A2 sensitive substrate |
|
|
|
tobacco (smoking) |
|
|
|
|
1A2 moderate inducer |
|
|
|
|
|
tolbutamide |
|
|
|
|
|
|
|
2C9 moderate sensitive substrate |
|
|
tolterodine |
|
|
|
|
|
|
2D6 sensitive substrate |
|
|
|
tolvaptan |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
tramadol |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
|
|
triazolam |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
trimethoprim |
|
|
2C8 weak inhibitor |
|
|
|
|
|
MATE1; MATE2-K inhibitor |
|
trimipramine |
|
|
|
|
|
|
|
2D6 moderate sensitive substrate |
|
|
vandetanib |
|
|
|
|
|
|
|
|
MATE1; MATE2-K inhibitor |
|
vardenafil |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
vemurafenib |
|
1A2 moderate inhibitor |
2D6 weak inhibitor |
|
|
3A4 weak inducer |
|
|
|
|
venetoclax |
|
|
|
|
|
|
3A4 sensitive substrate |
|
|
|
verapamil |
|
3A4 moderate inhibitor |
|
|
|
|
|
|
P-gp inhibitor |
|
voriconazole |
3A4 strong inhibitor |
2C19 moderate inhibitor |
2B6; 2C9; weak inhibitor |
|
|
|
|
2C9 moderate sensitive substrate |
|
|
warfarin18
|
|
|
|
|
|
|
|
2C9 moderate sensitive substrate |
|
|
zanubrutinib |
|
|
|
|
|
3A4 weak inducer |
|
|
|
|
zileuton |
|
|
1A2 weak inhibitor |
|
|
|
|
|
|
|
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.